Patients diagnosed with both atrial fibrillation and Alzheimer’s disease exhibit a slower rate of cognitive decline when treated with newer oral anticoagulant drugs known as NOACs, according to research published in the European Heart Journal by scientists at Karolinska Institutet. Drawing on nationwide Swedish registry data covering 7,308 individuals, the observational study found that patients taking NOACs experienced a significantly reduced drop in thinking and memory scores compared to those prescribed the older blood thinner warfarin or no anticoagulant medication.
Karolinska Institutet Study Tracks 7,308 Patients With Atrial Fibrillation and Alzheimer’s
Atrial fibrillation is a frequent irregular heartbeat condition among older adults that also coexists with Alzheimer’s disease in numerous patients, requiring doctors to weigh complex treatment choices to prevent blood clots and stroke. To evaluate how anticoagulants impact cognitive trajectories after a dementia diagnosis, researchers utilized information from SveDem, the Swedish Register for Cognitive Disorders/Dementia, linking it with national health registries covering diagnoses, prescriptions, and clinical outcomes. The study cohort comprised 7,308 people who had both conditions, with an average age of 82.6 years at their Alzheimer’s diagnosis, according to data detailed by Karolinska Institutet.
Participants were divided into three matched groups for analysis. One group received newer oral anticoagulants, a second group was treated with warfarin, and a third group received no anticoagulant medication at all. Researchers tracked changes in cognitive function over time using the Mini-Mental State Examination, a standardized test measuring orientation, memory, and thinking abilities.
Comparing NOACs, Warfarin, and Untreated Patients on MMSE Scores
Patients treated with NOACs showed a significantly slower decline in Mini-Mental State Examination scores than individuals taking warfarin or no anticoagulants, with the difference amounting to slightly more than 0.2 points per year. While that annual margin is modest for any single patient, researchers noted it could accumulate into a meaningful divergence over an extended period. “The difference is modest for an individual patient from one year to the next, but over a longer period even such an effect could influence how cognitive function develops,” Nanbo Zhu, a researcher at the Department of Neurobiology, Care Sciences and Society at Karolinska Institutet, explained in the published findings. After five years, estimated Mini-Mental State Examination scores remained higher among NOAC users compared to the other evaluated groups.
Did you know? Atrial fibrillation affects a substantial portion of older adults and can allow blood clots to form in the heart, which significantly elevates the risk of ischemic stroke if left untreated.
Mechanisms and Safety Outcomes of Anticoagulant Therapy
The potential advantages of blood thinners extend beyond slowing cognitive decline. According to the study data, patients treated with NOACs also experienced lower risks of death, stroke, blood clots, and fractures when compared to individuals who did not receive anticoagulants. Warfarin was similarly associated with reduced risks of death, stroke, and blood clots, but patients taking warfarin faced a higher risk of major bleeding complications.

Researchers point to vascular mechanisms to explain the cognitive findings. “There are reasons to believe that the treatment could have a positive effect on cognition, for example by improving blood flow and reducing small-scale damage in the brain,” stated Maria Eriksdotter, who led the study as a professor at the Department of Neurobiology, Care Sciences and Society at Karolinska Institutet and senior consultant in geriatric medicine at Karolinska University Hospital.
Study Limitations and Observational Design
Because the investigation relied on an observational design tracking real-world registry data rather than a randomized clinical trial, the authors emphasize that the results cannot definitively prove that NOACs directly caused the slower cognitive decline or health benefits. Unmeasured confounding factors that could influence both treatment assignment and health trajectories could not be entirely ruled out, and some participants may have switched medications during the follow-up period. Consequently, clinical trials are required to confirm whether the drugs themselves exert a protective effect on brain function.
Frequently Asked Questions
What are NOACs?
How was cognitive decline measured in the Karolinska Institutet study?
Researchers tracked cognitive function using the Mini-Mental State Examination, a standardized test that evaluates thinking, memory, and orientation over time.
Did warfarin slow cognitive decline as well?
Patients taking warfarin or no anticoagulants experienced a faster rate of cognitive decline compared to those treated with NOACs, though warfarin was associated with a higher risk of major bleeding.
What are your thoughts on these findings regarding blood thinners and cognitive health? Join the discussion by leaving a comment below, or explore our archive for more coverage on neurological research.